Neuralstem | Cafepharma

Neuralstem Rises on Publication of Alzheimer’s Stem Cell Therapy Data

Submitted by admin on Thu, 10/25/2018 - 11:46

snippet

The neural stem cell line into APP/PS1 mice that carry genes bearing mutations associated with onset of AD in humans
NSI-532.IGF1 is a second-generation cell therapy candidate that is engineered to combine neural stem cells with a neuroprotective protein, IGF-1

Source

CP Wire

Headline

Neuralstem Rises on Publication of Alzheimer’s Stem Cell Therapy Data

News Tags

Neuralstem

NSI-532.IGF1

Alzheimer's disease

Neuralstem Rises on Publication of Alzheimer’s Stem Cell Therapy Data

The neural stem cell line into APP/PS1 mice that carry genes bearing mutations associated with onset of AD in humans
NSI-532.IGF1 is a second-generation cell therapy candidate that is engineered to combine neural stem cells with a neuroprotective protein, IGF-1

FDA Grants Orphan Drug Designation to Neuralstem's Treatment for Angelman Syndrome

Submitted by admin on Thu, 08/09/2018 - 15:55

snippet

Neuralstem, Inc. (Nasdaq:CUR) announced on 8/9/18 that the U.S. Food and Drug Administration has granted orphan drug designation to NSI-189 for the treatment of Angelman syndrome.

Source

CP Wire

Headline

FDA Grants Orphan Drug Designation to Neuralstem's Treatment for Angelman Syndr…

News Tags

Neuralstem

Angelman Syndrome

NSI-189

FDA Grants Orphan Drug Designation to Neuralstem's Treatment for Angelman Syndrome

Neuralstem, Inc. (Nasdaq:CUR) announced on 8/9/18 that the U.S. Food and Drug Administration has granted orphan drug designation to NSI-189 for the treatment of Angelman syndrome.